Insulet Corporation announced a voluntary recall of specific lots of its Omnipod® 5 insulin‑delivery pods after discovering a manufacturing defect that can cause a small tear in the internal tubing, leading to insulin leakage and potential under‑delivery. The recall covers approximately 1.5 % of the company’s annual global production and includes 18 reports of serious adverse events, such as hospitalizations and diabetic ketoacidosis, with no deaths reported.
Customers can verify whether their pod is affected by entering the lot number on the company’s recall portal at omnipod.com/check‑pods. Insulet has committed to providing replacement pods at no cost and has notified the U.S. Food and Drug Administration. The company estimates the recall will cost up to $40 million in 2026, a figure that reflects the cost of replacements, logistics, and potential regulatory compliance expenses.
Insulet’s spokesperson emphasized that the recall does not alter the overall safety profile of the Omnipod 5 system and that all other pods and related products remain safe to use. The company also stated that it will continue to manufacture and ship Omnipod 5 pods and does not anticipate disruption to customer shipments, product availability, or new patient starts.
Management reiterated that patient safety and product quality remain the company’s highest priorities and that the recall is a precautionary measure to maintain product integrity. Insulet has implemented updates to its manufacturing processes and quality controls, although specific procedural changes were not disclosed in the announcement.
The recall has already triggered a market reaction, with the company’s shares falling nearly 7 % in extended trading. Analyst Mike Kratky of Leerink Partners described the news as an “unwelcome development” but noted that the recall is unlikely to shift Insulet’s market share in the short term. The company’s 2026 revenue guidance of 20 % to 22 % on a constant‑currency basis remains unchanged, reflecting confidence in its ability to manage the recall’s financial impact while sustaining growth.
Insulet’s history of product corrections—including a Class I recall of the Omnipod 5 Android app in late 2023/early 2024 and a correction for the Omnipod 5 controller’s charging port in 2022—may influence investor sentiment, but the company’s robust revenue growth of 30.73 % over the past twelve months and its 25.6 % market share in 2025 support its continued competitive position in the insulin pump market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.